Re-examination of participants from the Swedish CArdioPulmonary bioImage Study
Swedish CArdioPulmonary bioImage Study 2
Karolinska Institutet · NCT06679777
This study is looking at around 15,000 people from a previous heart and lung health study to see how their conditions have changed over the years and to improve ways to predict and prevent heart and lung diseases.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30154 (estimated) |
| Sex | All |
| Sponsor | Karolinska Institutet (other) |
| Locations | 6 sites (Gothenburg and 5 other locations) |
| Trial ID | NCT06679777 on ClinicalTrials.gov |
What this trial studies
The Swedish CArdioPulmonary bioImage Study 2 (SCAPIS 2) aims to re-examine approximately 15,000 individuals who participated in the original SCAPIS study, conducted between 2013 and 2018. This observational study will assess the progression of cardiovascular and lung diseases by utilizing various diagnostic methods, including CCTA, ECG, and spirometry, to gather data on risk factors and disease mechanisms. The study focuses on understanding the natural progression of atherosclerosis and lung function over an 8-10 year period, providing valuable insights into the long-term health of the participants. By comparing outcomes between those invited to SCAPIS 2 and those not invited, the study seeks to enhance prediction and prevention strategies for these diseases.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals who participated in the original SCAPIS study and are currently aged 58-74.
Not a fit: Patients who did not participate in SCAPIS 1 or have withdrawn their consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for predicting and preventing cardiovascular and lung diseases in the general population.
How similar studies have performed: Previous studies with similar longitudinal approaches have shown success in identifying risk factors and disease progression, indicating that this methodology is both tested and promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Participated in SCAPIS 1. Exclusion Criteria: * Individuals who have withdrawn their informed consent during or after SCAPIS 1.
Where this trial is running
Gothenburg and 5 other locations
- Gothenburg University — Gothenburg, Sweden (RECRUITING)
- Linköping University — Linköping, Sweden (RECRUITING)
- Lund University — Lund, Sweden (RECRUITING)
- Karolinska Institutet — Stockholm, Sweden (RECRUITING)
- Umeå Universitet — Umeå, Sweden (RECRUITING)
- Uppsala University — Uppsala, Sweden (RECRUITING)
Study contacts
- Principal investigator: Carl Johan Östgren, PhD — Linkoeping University
- Study coordinator: Tomas Jernberg, PhD
- Email: tomas.jernberg@ki.se
- Phone: +46-70-1671474
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cardiovascular Diseases, Lung Diseases